Following approval by the EMA in the European Union earlier in 2022, lenacapavir (Sunlenca®) received approval by the U.S. Food & Drug Administration (FDA) in December 2022.
Details from the U.S. Prescribing Information which pertain to specific drug interactions have now been added to the interaction database and are viewable on the website interaction checker alongside those from the European Summary of Product of Characteristics. (Note, the description field which contains product label details is not viewable on the HIV iChart version of the interaction checker.)
